Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 0.50 |
| ▸ | F7 | P08709 | 9/20 | 0.50 |
| ▸ | TMPRSS6 | Q8IU80 | 5/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860369 | 0.96 | F7 (0.53) | F2F7F10 | |
| Trifluoroacetic Acid SCHEMBL842198 | 0.83 | F7 (0.47) | F2F7TMPRSS6KLK1KLK5 | |
| Trifluoroacetic Acid SCHEMBL841182 | 0.81 | F7 (0.49) | F2F7KLK1KLK5F10 | |
| SCHEMBL841845 | 0.79 | F7 (0.55) | F2F7F10 | |
| SCHEMBL860431 | 0.78 | F7 (0.61) | F2F7F10 | |
| SCHEMBL861199 | 0.78 | F7 (0.61) | F2F7F10 | |
| SCHEMBL860287 | 0.77 | F7 (0.52) | F2F7F10 | |
| Trifluoroacetic Acid SCHEMBL841123 | 0.77 | F7 (0.46) | F2F7TMPRSS6F10 | |
| SCHEMBL8104704 | 0.76 | F7 (0.52) | F2F7F10 | |
| SCHEMBL3640208 | 0.75 | F7 (0.52) | F2F7F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | F7, F9, TFPI | F2 23/4885F7 1/4885TMPRSS6 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.